Updates are available Correction dated 2019-07-02
Click to view Correction: https://doi.org/10.1038/s41591-019-0535-y
-
Authors
Ribas, Antoni http://orcid.org/0000-0003-3669-8458
Lawrence, Donald
Atkinson, Victoria
Agarwal, Sachin
Miller, Wilson H. Jr
Carlino, Matteo S.
Fisher, Rosalie
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Hodi, F. Stephen
Tsoi, Jennifer
Grasso, Catherine S.
Mookerjee, Bijoyesh
Zhao, Qing
Ghori, Razi
Moreno, Blanca Homet
Ibrahim, Nageatte
Hamid, Omid
- License Information
-
More Information
Article History
Received: 24 November 2018
Accepted: 2 May 2019
First Online: 6 June 2019
Change Date: 2 July 2019
Change Type: Update
Change Details: This sentence was originally included in the legend for Extended Data Fig. 1: "*Nominal time after first dose. N denotes number of patients with samples for pharmacokinetic analysis." The sentence was deleted as no asterisk appeared in that figure.
Competing interests
: A.R. received personal fees for consulting from Amgen, Bristol-Myers Squibb, Chugai, Genentech–Roche, Merck–MSD and Novartis, and is on the scientific advisory board of, and holds stock in, Advaxis, Apricity, Arcus, Bioncotech, Compugen, CytomX, Five Prime, FLX Bio, ImaginAb, Isoplexis, Kite-Gilead, Merus, Rgenix, Lutris, PACT Pharma and Tango Therapeutics. V.A. received personal fees and non-financial support from Bristol-Myers Squibb and Merck Sharpe & Dohme, and personal fees only from Merck Serono, Novartis and Pierre Fabre. W.H.M. received personal fees from Bristol-Myers Squibb, Novartis, GlaxoSmithKline, Amgen and Roche. M.S.C. received personal fees from Merck Sharpe & Dohme, Novartis, Bristol-Myers Squibb and Pierre Fabre. R.F. received personal fees from Merck Sharpe & Dohme. G.V.L. received personal fees from Aduro, Amgen, Array, Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, Oncosec and Pierre Fabre. F.S.H. reports receiving personal fees from Merck, Bristol-Myers Squibb, EMD Serono, Celldex, Sanofi, and Novartis; other from Merck to his institution and he has a patent on MICA related disorders for which he receives royalties. B.M. reports employment and stock options at Novartis and stock options at GlaxoSmithKline. B.H.M., Q.Z., R.G. and N.I. report employment at Merck Sharp & Dohme. N.I. also holds stocks in Merck & Co. and GlaxoSmithKline. O.H. reports personal fees from Merck, during the conduct of the study; personal fees from Amgen, Novartis, Roche, Bristol-Myers Squibb, Genenetch, and contracted institutional support from AstraZeneca, Bristol-Myers Squibb, Celldex, Genentech, Immunocore, Incyte, Merck, MerckSerono, MedImmune, Novartis, Pfizer, Rinat and Roche. All other authors have no competing interests.
